Ef Institute For Cultural Exchange

The Broad Institute, a collaborative effort between MIT and Harvard, is dedicated to enhancing human health through multidisciplinary research focused on understanding and treating diseases. By bringing together scientists from various fields, Broad fosters innovation at the intersection of biology, artificial intelligence, and technology, driving significant advancements in biomedical science. With an array of specialized centers, the Broad Institute conducts groundbreaking research in areas such as cancer, brain health, and chronic diseases while actively engaging patients and partners to accelerate discovery and treatment development. The institute also emphasizes education and outreach, offering programs that connect art and science, as well as opportunities for students and educators to participate in its mission. Generated from the website

The MGH Institute for Technology Assessment (ITA) is a research institute located in Boston, MA. They specialize in assessing the impact of technology on various industries and sectors, including healthcare. The ITA conducts seminars, publishes research papers, and provides modeling tools and grants for research projects. They have a team of dedicated staff and collaborate with different labs to carry out their research. One of their recent publications focuses on the impact of COVID-19-related delays on endocrine surgery patients. The study found that although some patients experienced disease progression during the delays, most patients with follow-up did not. The research suggests that temporary delays in endocrine-related surgical care may be acceptable in extreme circumstances. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.